New initiative aims at reducing adverse effects of medications in individuals with mental illnesses

Geneticists at the University of Pittsburgh Graduate School of Public Health will provide their scientific expertise to a new initiative aimed at preventing and reducing the adverse effects of medications in people with mental illnesses.

The research project will take a personalized medicine approach to managing drug therapy by analyzing each patient's genetic makeup to determine potential adverse reactions to medications. Funded by the Polk Foundation, it will be led by NHS Human Services, one of the nation's largest providers of human services, in collaboration with Pitt Public Health; CareKinesis Inc., a medication therapy management services provider; and Coriell Life Sciences, a pharmacogenomics testing vendor.

"An individual's genetic makeup defines how many common drugs are processed by the body and who is at risk for an adverse drug response from such therapies," said Dietrich Stephan, Ph.D., professor and chair of the Department of Human Genetics at Pitt Public Health. "Individuals can suffer immensely from the very drugs that are meant to improve their health if given drugs they cannot tolerate, often resulting in increased emergency room visits and elevated health care costs."

For example, some people are genetically predisposed to metabolize certain drugs faster than the average person, causing them to have a stronger, more immediate response to medication. When someone is prescribed multiple medications, such responses can cause unexpected and potentially dangerous drug interactions.

"The people at highest risk, such as the aged and mentally ill, often are prescribed a multitude of drugs with no insight into their genetic susceptibilities," said Dr. Stephan, who also serves as associate director of the Institute for Personalized Medicine, a collaboration between Pitt and UPMC. "In this study, we aim to systematically implement comprehensive genetic testing in these populations and develop the evidence around improved outcomes and reduced costs that allows such testing to be broadly delivered to the general population and reimbursed by insurers. The Institute for Personalized Medicine, as part of UPMC, has the scale to be able to broadly implement pharmacogenomics to improve lives across a multitude of providers both nationally and internationally."

Dr. Stephan serves as chair of the clinical advisory panel for the 28-month, $350,000 initiative, which is funded by a grant from the Polk Foundation to NHS Human Services Foundation, the charitable arm of NHS Human Services.

"Our primary goal is to increase the quality of life for individuals in behavioral health services, and the funding received to conduct this important research is a significant step in the right direction," said Joe Martz, chief executive officer of NHS Human Services.

Source:

University of Pittsburgh Schools of the Health Sciences

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Black/African American prostate cancer patients treated with darolutamide show outcomes similar to the overall population